Physician profile
Gregory A May
NPI 1619984168
$3,618.26
in general payments reported to CMS, 2019-2025
36 companies · $460 in 2025
The $460 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $479 · 2021: $460 · 2022: $776 · 2023: $565 · 2024: $490 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.16 | 2019-2025 | |
| Astellas Pharma US INC | $437.57 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $406.18 | 2020-2024 | Injectafer |
| Coopersurgical, INC. | $394.53 | 2021-2024 | Advincula Delineator Uterine Manipulator, Supercut Hysterectomy Scissors |
| Bayer Healthcare Pharmaceuticals INC. | $379.68 | 2019-2023 | |
| Allergan, INC. | $131.24 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $126.66 | 2023-2025 | Myfembree, Gemtesa |
| Ethicon US, LLC | $107.86 | 2019-2023 | Dermabond Prineo |
| Smith+Nephew, INC. | $106.00 | 2019-2020 | |
| Organon LLC | $91.74 | 2021-2025 | Nexplanon |
| Baudax Bio INC. | $88.38 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.23 | 2019-2025 | M-M-R II, Gardasil 9 |
| Acessa Health INC. | $80.83 | 2021 | |
| Pfizer INC. | $65.05 | 2021-2024 | |
| Hologic Sales and Service, LLC | $57.65 | 2022-2023 | Acessa Provu System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $53.04 | 2024-2025 | Zepbound |
| Applied Medical Resources Corporation | $40.30 | 2022 | |
| Novo Nordisk INC | $39.11 | 2020-2022 | |
| Exeltis, USA INC. | $36.37 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $36.13 | 2025 | NP Thyroid 60 |
| Baxter Healthcare | $34.91 | 2022-2023 | Perclot |
| Innovation Technologies INC | $34.87 | 2023 | Irrisept |
| Sage Therapeutics, LLC | $33.65 | 2019-2024 | |
| Minerva Surgical, INC | $25.31 | 2022 | |
| Boston Scientific Corporation | $25.28 | 2025 | Bulkamid |
| Therapeuticsmd, INC. | $24.76 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $22.62 | 2025 | Exparel |
| Caldera Medical, INC | $19.00 | 2021 | |
| Urovant Sciences INC | $17.38 | 2022 | |
| Myovant Sciences INC. | $17.24 | 2021 | |
| Coloplast Corp | $16.60 | 2024 | |
| Medtronic, INC. | $14.74 | 2025 | Ligasure |
| Avion Pharmaceuticals | $14.28 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $13.60 | 2019 | |
| Lupin INC. | $12.89 | 2019 | |
| Mayne Pharma Commercial LLC | $12.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.